CARE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CARE is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a constructive technical setup and very bullish options positioning, but the recent sharp price drop, insider selling, and analyst downgrades make the entry less attractive today. Since the investor is impatient and does not want to wait for an ideal entry, the best direct call is hold rather than buy.
CARE is still in an overall bullish trend technically: SMA_5 is above SMA_20 and SMA_20 is above SMA_200, which supports upward momentum. MACD histogram is positive at 0.165, though it is contracting, suggesting momentum is still positive but losing some strength. RSI_6 at 57.437 is neutral, so the stock is not overbought or oversold. Price closed at 32.75, just below the pivot level of 32.811, with near-term resistance at 34.527 (R1) and 35.586 (R2), and support at 31.096 (S1). The recent regular-session drop of 4.22% weakens the short-term setup even though the broader trend remains intact.
No news in the recent week, so there is no fresh event-driven catalyst. The main positives are the bullish technical trend, strong call-heavy options sentiment, and analyst commentary earlier in the year that highlighted improved balance sheet flexibility after the sale of nonperforming loans. The stock trend model also points to positive forward returns over the next day, week, and month.
The stock fell sharply in the latest session, and insider selling has increased 423.90% over the last month, which is a clear negative signal. Analyst sentiment has also softened recently, with Raymond James and Hovde both downgrading the stock to Market Perform, and Freedom Broker downgrading to Hold. There is no recent news catalyst to support a fresh upside move, and hedge funds are neutral.
No usable latest-quarter financial snapshot was available because the financial data returned an error. However, prior analyst notes indicate the company benefited from the sale of non-performing loans, which improved EPS and strengthened the balance sheet. The most recently referenced seasonal context was Q2, when analysts expected net interest margin and expenses to improve meaningfully as liquidity was redeployed into higher-yielding assets.
Recent analyst trend has turned less positive. Raymond James downgraded CARE to Market Perform from Outperform on 2026-07-01, citing valuation after a strong year-to-date run, while still remaining constructive on the outlook. Hovde also downgraded the stock to Market Perform and raised its target to $30. Freedom Broker downgraded to Hold with a target of $27. Earlier in April, Raymond James had been bullish and raised its target to $27 from $25 with an Outperform rating. Overall Wall Street view: pros see improving balance sheet quality, better capital flexibility, and potential margin improvement; cons see valuation becoming stretched after the rally, leading to more neutral ratings.
